Browsing by Author "Türker, Alev"
Now showing items 1-2 of 2
-
Nivolumab for relapsed or refractory hodgkin lymphoma experience in Turkey
Ferhanoğlu, Burhan; Beköz, Hüseyin Saffet; Karadurmuş, Nuri; Paydaş, Semra; Gülbaş, Zafer; Türker, Alev; Toptaş, Tayfur; Fıratlı Tuğlular, Tülin; Tekgündüz, Emre; Kaya, Ali Hakan; Taştemir, N.; Arat, Mutlu; Pepedil Tanrıkulu, Funda; Özkocaman, Vildan; Abalı, Hüseyin; Turgut, Mehmet; Kaynar, Leylagül; Karadoğan, İhsan; Özbalak, Murat; Özcan, Muhit; Doğu, Mehmet Hilmi; Kabukçu Hacıoğlu, Sibel; Yıldırım, Rahsan; Barışta, İbrahim; Demirkaya, Metin; Köseoğlu, Fatoş Dilan; Yüksel, Meltem Kurt; Sönmez, Mehmet; Toprak, Selami Koçak (Ferrata Storti Foundation, 2017)… -
Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience
Beköz, Hüseyin; Özbalak, Murat; Karadurmuş, Nuri; Paydaş, Semra; Türker, Alev; Toptaş, Tayfur; Fıratlı Tuğlular, Tülin; Altuntaş, Fevzi; Kızıl Çakar, Merih; Sönmez, Mehmet; Gülbaş, Zafer; Demir, Nazlı; Kaynar, Leylagül; Yıldırım, Rahşan; Karadoğan, İhsan; Arat, Mutlu; Kapucu, İrem; Alayvaz Aslan, Nevin; Özkocaman, Vildan; Turgut, Mehmet; Kurt Yüksel, Meltem; Özcan, Muhit; Kabukçu Hacıoğlu, Sibel; Barışta, İbrahim; Demirkaya, Metin; Saydam, Güray; Toprak, Selami Koçak; Yılmaz, Mehmet; Demirkol, Onur; Ferhanoğlu, Burhan (Springer, 2020)Classical Hodgkin lymphoma (cHL) is considered a curable disease; however, in approximately one-third of the responding patients, the disease relapses following completion of therapy. One of the drugs that have been approved ...
